ATE423778T1 - Verfahren zur herstellung von anthranilsäurederivat-hydrat - Google Patents
Verfahren zur herstellung von anthranilsäurederivat-hydratInfo
- Publication number
- ATE423778T1 ATE423778T1 AT03727661T AT03727661T ATE423778T1 AT E423778 T1 ATE423778 T1 AT E423778T1 AT 03727661 T AT03727661 T AT 03727661T AT 03727661 T AT03727661 T AT 03727661T AT E423778 T1 ATE423778 T1 AT E423778T1
- Authority
- AT
- Austria
- Prior art keywords
- hydrate
- acid derivative
- anthranilic acid
- filtrate
- pharmaceutically acceptable
- Prior art date
Links
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 4
- 239000000706 filtrate Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000010792 warming Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37975902P | 2002-05-14 | 2002-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE423778T1 true ATE423778T1 (de) | 2009-03-15 |
Family
ID=29420557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03727661T ATE423778T1 (de) | 2002-05-14 | 2003-05-13 | Verfahren zur herstellung von anthranilsäurederivat-hydrat |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7524861B2 (https=) |
| EP (1) | EP1506188B1 (https=) |
| JP (1) | JP4464814B2 (https=) |
| KR (1) | KR101060971B1 (https=) |
| CN (1) | CN100349888C (https=) |
| AT (1) | ATE423778T1 (https=) |
| AU (1) | AU2003233899B2 (https=) |
| BR (1) | BR0309990A (https=) |
| CA (1) | CA2485430C (https=) |
| DE (1) | DE60326341D1 (https=) |
| WO (1) | WO2003095447A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| CA2634113A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| GB0706072D0 (en) * | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| SI2408750T1 (sl) | 2009-03-20 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2819670A1 (en) | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| PE20160605A1 (es) | 2013-07-30 | 2016-07-20 | Gilead Connecticut Inc | Formulaciones de inhibidores de la syk |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
| CN104434947B (zh) * | 2014-11-07 | 2016-11-09 | 滨州医学院附属医院 | 一种抗胆管癌的药物组合物及其应用 |
| EP3378858A1 (en) * | 2017-03-21 | 2018-09-26 | Bioprojet | Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same |
| EP3672974A1 (en) | 2017-08-25 | 2020-07-01 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| US11339168B2 (en) | 2019-02-22 | 2022-05-24 | Kronos Bio, Inc. | Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors |
| AU2021358977A1 (en) * | 2020-10-07 | 2023-04-27 | Health Hope Pharma Hk Limited | Acetamido-phenylbenzamide derivatives and methods of using the same |
| CN112724124A (zh) * | 2021-01-18 | 2021-04-30 | 林剑雄 | 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用 |
| CN117304105A (zh) * | 2023-08-18 | 2023-12-29 | 中国科学院基础医学与肿瘤研究所(筹) | 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100220538B1 (ko) * | 1991-01-11 | 1999-09-15 | 뮈쉘 쥐르밀 | 아크리딘 유도체 |
| CN100354265C (zh) * | 1996-10-18 | 2007-12-12 | 埃克森诺瓦有限公司 | 邻氨基苯甲酸衍生物及其制备方法和作为多种抗性调节剂的用途 |
| GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
-
2003
- 2003-05-13 KR KR1020047018344A patent/KR101060971B1/ko not_active Expired - Fee Related
- 2003-05-13 CN CNB038159295A patent/CN100349888C/zh not_active Expired - Fee Related
- 2003-05-13 CA CA2485430A patent/CA2485430C/en not_active Expired - Fee Related
- 2003-05-13 WO PCT/GB2003/002060 patent/WO2003095447A1/en not_active Ceased
- 2003-05-13 US US10/513,986 patent/US7524861B2/en not_active Expired - Fee Related
- 2003-05-13 AT AT03727661T patent/ATE423778T1/de not_active IP Right Cessation
- 2003-05-13 AU AU2003233899A patent/AU2003233899B2/en not_active Ceased
- 2003-05-13 EP EP03727661A patent/EP1506188B1/en not_active Expired - Lifetime
- 2003-05-13 BR BR0309990-3A patent/BR0309990A/pt not_active IP Right Cessation
- 2003-05-13 DE DE60326341T patent/DE60326341D1/de not_active Expired - Lifetime
- 2003-05-13 JP JP2004503463A patent/JP4464814B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050009706A (ko) | 2005-01-25 |
| AU2003233899A1 (en) | 2003-11-11 |
| CA2485430A1 (en) | 2003-11-20 |
| JP2005538051A (ja) | 2005-12-15 |
| CA2485430C (en) | 2011-12-06 |
| CN100349888C (zh) | 2007-11-21 |
| DE60326341D1 (de) | 2009-04-09 |
| US20050222199A1 (en) | 2005-10-06 |
| US7524861B2 (en) | 2009-04-28 |
| WO2003095447A1 (en) | 2003-11-20 |
| KR101060971B1 (ko) | 2011-09-01 |
| EP1506188B1 (en) | 2009-02-25 |
| JP4464814B2 (ja) | 2010-05-19 |
| BR0309990A (pt) | 2005-02-22 |
| CN1665806A (zh) | 2005-09-07 |
| EP1506188A1 (en) | 2005-02-16 |
| AU2003233899B2 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE423778T1 (de) | Verfahren zur herstellung von anthranilsäurederivat-hydrat | |
| CN104936961B (zh) | (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法 | |
| NO20052912L (no) | Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil | |
| US11897843B2 (en) | Process for the preparation of enantiomerically enriched 3-aminopiperidine | |
| ATE366725T1 (de) | Verfahren zur herstellung von gereinigten 1,3- substituierten imidazoliumsalzen | |
| ES2706314T3 (es) | Método para la producción de praziquantel y precursores del mismo | |
| JP2010090174A (ja) | 新規ナテグリニド結晶 | |
| ATE299144T1 (de) | Verfahren zur herstellung einer pharmazeutisch aktiven verbindung (granisetron) | |
| JP2010510253A5 (https=) | ||
| ATE515496T1 (de) | Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure | |
| RU2006102357A (ru) | Способ управления кристаллической структурой ризедроната | |
| RU2387656C2 (ru) | Способ получения гидробромида галантамина | |
| ATE297933T1 (de) | Ein verfahren zur herstellung von hochreinem cefpodoxim-proxetil | |
| ATE316082T1 (de) | Prozess zur herstellung von r(+)alpha-liponsäure | |
| ATE325797T1 (de) | Verfahren zur herstellung von hochreinem triethylendiamin | |
| DE50307171D1 (de) | Verfahren zur herstellung von 3-amidinophenylalanin-derivaten | |
| ATE403658T1 (de) | Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda) | |
| ATE402157T1 (de) | Verfahren zur herstellung von mycophenolatmofetil | |
| ATE370950T1 (de) | Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol | |
| DE602006015241D1 (de) | Verbessertes verfahren zur herstellung von rivastigmin | |
| DE602004020050D1 (de) | Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte | |
| JPH1036327A (ja) | １−（３−メトキシフェニル）エチルアミンの光学活性体の製造方法 | |
| ATE375355T1 (de) | Verfahren zur herstellung von cefpodoxim-proxetil | |
| JP2009062392A (ja) | 環化法 | |
| BR112020009568A2 (pt) | Método de produção de composto intermediário para síntese de medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |